In vitro activity of cefiderocol in combination with new β-lactam/β-lactamase inhibitor combinations (βL-βLICs) against multidrug resistant KPC-producing Klebsiella pneumoniae

J Antibiot (Tokyo). 2023 Nov;76(11):682-688. doi: 10.1038/s41429-023-00653-8. Epub 2023 Aug 30.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins
  • Cefiderocol
  • Cephalosporins / pharmacology
  • Drug Combinations
  • Humans
  • Klebsiella Infections*
  • Klebsiella pneumoniae
  • Lactams
  • Microbial Sensitivity Tests
  • beta-Lactamase Inhibitors* / pharmacology
  • beta-Lactamases

Substances

  • beta-Lactamase Inhibitors
  • Lactams
  • Cephalosporins
  • Anti-Bacterial Agents
  • beta-Lactamases
  • Drug Combinations
  • Bacterial Proteins